Ionis reported second-quarter 2026 results with total revenue of $268 million and a GAAP net loss of $115 million for the quarter. The company ended June 30, 2026 with $2.055 billion in cash, cash equivalents and short-term investments and reiterated it is on track for 2026 financial guidance. Management highlighted early commercial momentum for TRYNGOLZA and continued launches and regulatory milestones across its neurology and infectious disease portfolio.

Financial Highlights

  • Total revenue: $268 million for the three months ended June 30, 2026; $514 million for the six months ended June 30, 2026.
  • Commercial revenue: $119 million for Q2 2026; $226 million for the six months ended June 30, 2026.
  • Operating expenses (GAAP): $370 million in Q2 2026 and $734 million for the six months ended June 30, 2026; non-GAAP operating expenses: $325 million in Q2 2026 and $645 million for the six months.
  • Income (loss) from operations (GAAP): loss of $102 million in Q2 2026; non-GAAP loss from operations: $57 million in Q2 2026.
  • Net income (loss) (GAAP): loss of $115 million in Q2 2026; basic and diluted loss per share: $0.69 for the quarter.

Business Highlights

  • TRYNGOLZA (olezarsen): FDA approval in late June 2026 for adults with severe hypertriglyceridemia (sHTG) and for familial chylomicronemia syndrome (FCS); generated U.S. net product sales of $5 million in Q2 and $32 million year-to-date; sHTG U.S. launch showing early momentum and EU sHTG application under review.
  • DAWNZERA (donidalorsen): Continued commercial rollout with U.S. net product sales of $26 million in Q2 and $42 million year-to-date; launches outside the U.S. underway with new EU approvals.
  • Zilganersen: NDA under FDA Priority Review for Alexander disease with a PDUFA target action date of September 22, 2026; license agreement executed with Recordati for ex-U.S. development and commercialization.
  • Obudanersen (Angelman syndrome): Completed enrollment in Phase 3 REVEAL study; topline data anticipated in H2 2027.
  • Pipeline and partnered programs: Multiple upcoming milestones—global launch plans for bepirovirsen (chronic hepatitis B) with U.S. PDUFA Oct 26, 2026; pelacarsen cardiovascular outcomes (HORIZON) results expected; mixed CARDIO-TTRansform results for eplontersen presented as missed primary endpoint in overall ATTR-CM population but nominal significance in a pre-specified subgroup.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.